Arvinas Inc

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director